Upstream / Downstream

Explore pathways related to this product.

Our U.S. Offices Will Be Closing Early

Our U.S. offices will be closing early on November 24th at 6:00 PM EST.

To Purchase # 6251S

6251S 300 µl (3 nmol) $249.00
$ 0. 00

Questions?

Find answers on our FAQs page.

ANSWERS  

Visit PhosphoSitePlus®

PTM information and tools available.

LEARN MORE

REACTIVITY
H

Western blot analysis of extracts from HeLa cells, transfected with non-targeted siRNA (-) or SignalSilence® PTEN siRNA I (+) using PTEN Antibody #9552 and p42 MAP Kinase (Erk2) Antibody #9108. The PTEN antibody confirms silencing of PTEN expression, while the p42 MAPK antibody is used to control for loading and specificity of PTEN siRNA.

Learn more about how we get our images

Fluorescent detection of SignalSilence® Control siRNA (Fluorescein Conjugate) #6201 in living HeLa cells 24 hours post-transfection, demonstrating nearly 100% transfection efficiency.

Learn more about how we get our images
Image

Product Usage Information

CST recommends transfection with 100 nM PTEN siRNA I 48 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.


Storage: SignalSilence® siRNA is supplied in RNAse-free water. Aliquot and store at -20ºC.

Product Description

SignalSilence® PTEN siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit PTEN expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.


PTEN (phosphatase and tensin homologue deleted on chromosome ten), also referred to as MMAC (mutated in multiple advanced cancers) phosphatase, is a tumor suppressor implicated in a wide variety of human cancers (1). PTEN encodes a 403 amino acid polypeptide originally described as a dual-specificity protein phosphatase (2). The main substrates of PTEN are inositol phospholipids generated by the activation of the phosphoinositide 3-kinase (PI3K) (3). PTEN is a major negative regulator of the PI3K/Akt signaling pathway (1,4,5). PTEN possesses a carboxy-terminal, noncatalytic regulatory domain with three phosphorylation sites (Ser380, Thr382, and Thr383) that regulate PTEN stability and may affect its biological activity (6,7). PTEN regulates p53 protein levels and activity (8) and is involved in G protein-coupled signaling during chemotaxis (9,10).


1.  Wan X and Helman LJ (2003) Oncogene 22, 8205–11

2.  Myers, M.P. et al. (1997) Proc Natl Acad Sci USA 94, 9052-7.

3.  Myers, M.P. et al. (1998) Proc Natl Acad Sci USA 95, 13513-8.

4.  Wu, X. et al. (1998) Proc Natl Acad Sci USA 95, 15587-91.

5.  Vazquez, F. et al. (2000) Mol Cell Biol 20, 5010-8.

6.  Torres, J. and Pulido, R. (2001) J Biol Chem 276, 993-8.

7.  Freeman, D.J. et al. (2003) Cancer Cell 3, 117-30.

8.  Funamoto, S. et al. (2002) Cell 109, 611-23.

9.  Cantley, L.C. and Neel, B.G. (1999) Proc Natl Acad Sci USA 96, 4240-5.

10.  Iijima, M. and Devreotes, P. (2002) Cell 109, 599-610.


Entrez-Gene Id 5728
Swiss-Prot Acc. P60484


For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
SignalSilence® is a trademark of Cell Signaling Technology, Inc.
Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.